The Blue Box Biomedical Solutions
Barcelona · Founded 2021
About The Blue Box Biomedical Solutions
Breast cancer is the most treatable cancer, yet it remains the leading cause of death by cancer in women’largely because national screening programs miss up to 1 in 3 cases. The problem is even worse for women with dense breasts, who make up 50% of the screening population and for whom mammography is less reliable. At The Blue Box, we've developed a urine-based breast cancer test with a sensitivity of 88.42%, outperforming mammography by 15% overall’and by 30% in women with dense breasts. We're launching clinical trials in 2025 and bringing our test to gynecology clinics by 2026.
Company Facts
- Founded: 2021
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $4.4M
- Funding stage: Seed
- Last round: Seed (Nov 2025)
- Website: https://thebluebox.ai
- Phone: [email protected]
Industries & Categories
Artificial Intelligence (AI), Health Care, Internet of Things, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/the-blue-box-biomedical-solutions-118642 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.